Natera Company Profile (NASDAQ:NTRA)

Natera trades on the NASDAQ under the ticker symbol "NTRA."

Natera, Inc. (NASDAQ:NTRA) posted its earnings results on Tuesday, May, 9th. The company reported ($0.70) earnings per share for the quarter, missing analysts' consensus estimates of ($0.61) by $0.09. The business earned $46.90 million during the quarter, compared to the consensus estimate of $42.82 million. Natera had a negative return on equity of 101.63% and a negative net margin of 60.89%. The business's quarterly revenue was down 24.2% on a year-over-year basis. During the same quarter last year, the firm earned ($0.17) earnings per share. View Natera's Earnings History.

4 equities research analysts have issued 1 year price objectives for Natera's stock. Their predictions range from $14.00 to $20.00. On average, they anticipate Natera's stock price to reach $17.50 in the next twelve months. View Analyst Ratings for Natera.

Here are some recent quotes from research analysts about Natera stock:

• 1. According to Zacks Investment Research, "Natera, Inc. offers genetic testing and diagnostics with proprietary bioinformatics and molecular technology. Natera, Inc. is headquartered in San Carlos, California. " (7/12/2017)
• 2. Cowen and Company analysts commented, "Subsequent to the company's Q4 conference call (last week), we are reducing our estimates to reflect management commentary and 2017 guidance. While we believe the risk/reward is likely attractive at current levels, we are also reducing our price target to reflect our new revenue forecast and the heavy-H2 weighting of 2017 expectations...NTRA reported Q4 results last week and provided 2017 revenue guidance. In advance of the company's conference call (link to note), we had reduced our revenue estimates for Q4 and for 2017, by $1.5MM and $13MM, respectively, to reflect our estimated impact of the termination of the company's distribution agreement with BioReference Labs. Our reductions put us at the low end of the range of sell side estimates. Unfortunately, our estimates were not low enough for either period. Shares have traded off ~15% since the announcement and are off nearly 30% YTD." (3/14/2017)

Some companies that are related to Natera include BioTelemetry (BEAT), Kindred Healthcare (KND), Omeros Corporation (OMER), Acorda Therapeutics (ACOR), Aduro Biotech (ADRO), Synergy Pharmaceuticals (SGYP), Immunomedics (IMMU), Irhythm Tech (IRTC), Cellectis S.A. (CLLS), Mazor Robotics (MZOR), Albany Molecular Research (AMRI), Ascendis Pharma A/S (ASND), Luminex Corporation (LMNX), Achaogen (AKAO), PTC Therapeutics (PTCT), Heron Therapeutics (HRTX), NeuroDerm (NDRM) and ZIOPHARM Oncology (ZIOP).

Natera's management team includes the folowing people:

• Matthew Rabinowitz Ph.D., Chairman of the Board, President, Chief Executive Officer, Co-Founder
• Jonathan Sheena, Co-Founder, Chief Technology Officer, Director
• Michael Burkes Brophy, Chief Financial Officer
• Roelof Frederick Botha, Lead Independent Director
• Todd C. Cozzens, Independent Director
• Edward C. Driscoll Jr. Ph.D., Independent Director
• James I. Healy M.D. Ph.D., Independent Director
• Gail Boxer Marcus, Independent Director

(NTRA) raised $101 million in an initial public offering (IPO) on Thursday, July 2nd 2015. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Morgan Stanle, Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and Baird and Wedbush Pacgrow were co-managers.

Natera's stock is owned by a number of of retail and institutional investors. Top institutional investors include Sofinnova Management VIII L.L.C. (2.93%), Capital Impact Advisors LLC (0.11%) and Bank of Montreal Can (0.02%). Company insiders that own Natera stock include Herm Rosenman, Jonathan Sheena, Matthew Rabinowitz and Roelof Botha. View Institutional Ownership Trends for Natera.

Natera's stock was sold by a variety of institutional investors in the last quarter, including Capital Impact Advisors LLC. Company insiders that have sold Natera stock in the last year include Herm Rosenman, Jonathan Sheena and Matthew Rabinowitz. View Insider Buying and Selling for Natera.

Shares of Natera can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Natera stock can currently be purchased for approximately $9.23.